Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Katsuyoshi Takata, MD PhD, Lauren C. Chong, MSc, Avinash Thakur, PhD, Tomohiro Aoki, MD PhD, Anja Mottok, MD PhD, Elizabeth Chavez, BSc, Cg RT, Pedro Farinha, MD PhD, Graham W Slack, MD, Pamela Hoodles, Sohrab P Shah, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 1509.

https://doi.org/10.1182/blood-2019-129730

Published: 2019

Journal Articles

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Victor Bobée, PharmD, Fanny Drieux, MD, Vinciane Marchand, Vincent Sater, Liana Veresezan, MD, Jean-Michel Picquenot, MD, Pierre-Julien Viailly, Marie-delphine Lanic, Mathieu Viennot, Elodie Bohers, PhD, Lucie Oberic, MD, Christiane Copie-Bergman, MD PhD, Thierry Jo Molina, MD PhD, Philippe Gaulard, MD PhD, Corinne Haioun, MD PhD, Gilles A. Salles, MD PhD, Herve Tilly, MD PhD, Fabrice Jardin, Philippe Ruminy, PhD

Blood (2019) 134 (Supplement_1): 1476.

https://doi.org/10.1182/blood-2019-122405

Published: 2019

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

https://doi.org/10.1182/blood-2019-129131

Published: 2019

Journal Articles

Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd

Joshua D Brandstadter, MD PhD, Eric Perkey, Brian T. Gaudette, PhD, Léolène Carrington, PhD, Daniela Gomez-Atria, PhD, Bruce R. Blazar, MD, Burkhard Ludewig, PhD, Anastasia Tikhonova, PhD, Iannis Aifantis, PhD, David Allman, PhD, Ivan Maillard, MD PhD

Blood (2019) 134 (Supplement_1): 588.

https://doi.org/10.1182/blood-2019-123533

Published: 2019

Journal Articles

The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression

Costanza Zanetti, MSc, Joscha Ender, Mark Hartmann, Joschka Hey, MSc, BSc, Parimala Sonika Godavarthy, MSc, Eva Weissenberger, Rahul Kumar, PhD, Markus Metzler, MD PhD, Zhaohui Gu, PhD, Kathryn G. Roberts, PhD, Natalie Filmann, Clara D. Bloomfield, MD, Wendy Stock, MD, Charles G. Mullighan, MBBS, MD, Daniel B. Lipka, Daniela S. Krause, MD

Blood (2019) 134 (Supplement_1): 2748.

https://doi.org/10.1182/blood-2019-122797

Published: 2019

Journal Articles

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

Lei Fan, MD PhD, Chao Wang, Zhiqiang Wang, Xian Zhang, Lei Cao, Yi Miao, MD PhD, Xinyi Du, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 5306.

https://doi.org/10.1182/blood-2019-129469

Published: 2019

Journal Articles

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Edward Briercheck, MD, Marcos Mauricio Siliézar Tala, MD, Yasodha Natkunam, MD PhD, David M. Weinstock, MD, Oscar Silva, MD PhD

Blood (2019) 134 (Supplement_1): 5278.

https://doi.org/10.1182/blood-2019-131620

Published: 2019

Journal Articles

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Sheila K Pierson, MS, Laura Katz, MA, Christopher Sheild Nabel, MD PhD, Jason R Ruth, PhD, Sheila Diamond, MS, CGC, Hrishikesh Karvir, PhD, Fanyi Zhang, MS, Manjula P Reddy, MS, MSc, Mary Guilfoyle, MS, Craig Tendler, MD, Frits van Rhee, MD PhD, Philip Beineke, MS, Ana B Oromendia, PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2019) 134 (Supplement_1): 3599.

https://doi.org/10.1182/blood-2019-128284

Published: 2019

Journal Articles

Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing

Sarah Haebe, MD, Tanaya Shree, MDPhDBA, Anuja Sathe, PhD, Grady Day, HoJoon Lee, PhD, Debra K. Czerwinski, BA, Susan Grimes, BSc, Hanlee Ji, MD, Ronald Levy, MD

Blood (2019) 134 (Supplement_1): 297.

https://doi.org/10.1182/blood-2019-129445

Published: 2019

Journal Articles

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Blood (2019) 134 (Supplement_1): 657.

https://doi.org/10.1182/blood-2019-122663

Published: 2019

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

V. Koneti Rao, MD FRCPA, Sharon Webster, BSN, Virgil A.S.H. Dalm, MD, Anna Sediva, MD, P. Martin van Hagen, H. Michael Do, MD, Les Folio, MD, Maciej Cabanski, Marie-Anne Valentin, Stefan de Buck, Christoph Kalis, Anke Hasselberg, Christoph Burkhart, Klaus Kucher, MD, Birgitte Sloth, Gulbu Uzel, MD

Blood (2018) 132 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2018-99-113426

Published: 2018

Journal Articles

Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients

Anna Wing, Wenzhao Meng, PhD, Gerald Wertheim, MD, PhD, Dale Frank, MD, Michele Paessler, D.O., Megan S. Lim, MD, PhD, Eline T. Luning Prak, MD, PhD, David C Fajgenbaum, MD MBA, MSc, Vinodh Pillai, MD, PhD

Blood (2018) 132 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2018-99-116487

Published: 2018

Journal Articles

TFL Deletion Induces Incredible CXCL13 Secretion and Cachexia in Vavp - Bcl2 T ransgenic Mice

Kentaro Minagawa, MDPhD, Kanako Wakahashi, MD PhD, Fukui Chie, Shinichiro Nishikawa, MD PhD, Noboru Asada, MD PhD, Yuko Kawano, MD PhD, Hiroki Kawano, MD PhD, Tomohide Suzuki, MD, Shinichi Ishii, MD, Yoshio Katayama, MD PhD, Toshimitsu Matsui, MD PhD

Blood (2018) 132 (Supplement 1): 3908.

https://doi.org/10.1182/blood-2018-99-114351

Published: 2018

Journal Articles

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Sheila K Pierson, MS, Aaron James Stonestrom, MDPhD, Jason R Ruth, PhD, Dustin Shilling, PhD, Hongzhe Li, PhD, Yue Ren, MS, Katie Stone, BS, Frits van Rhee, MD PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2017) 130 (Supplement 1): 3592.

https://doi.org/10.1182/blood.V130.Suppl_1.3592.3592

Published: 2017

Journal Articles

Defective Notch Activation in Mesenchymal Cells Contributes to Myeloproliferative Neoplasm in Aged Mice

Young-Woong Kim, PhD, Sonia Rodriguez, PhD, Lin Wang, PhD, Guido Marcucci, MD, Amy Zollman, Nadia Carlesso, MD PhD

Blood (2017) 130 (Supplement 1): 134.

https://doi.org/10.1182/blood.V130.Suppl_1.134.134

Published: 2017

Journal Articles

BTK Cys481Ser Mutation Drives Ibrutinib Resistance through ERK1/2 Hyperactivation, and Can Confer a Protective Effect on Bystander Waldenstrom's Macroglobulinemia and ABC DLBCL Cells through Paracrine Mediated Pro-Survival Signaling

Jiaji Chen, BS, Xia Liu, MD, Manit Munshi, MS, Lian Xu, Nickolas Tsakmaklis, BA, Maria Demos, BS, Amanda Kofides, BS, Maria Luisa Guerrera, MD, Gloria Chan, MS, Zachary Hunter, PhD, Christopher Patterson, MAcc, Joshua Gustine, Jorge J. Castillo, MD, Steven P Treon, MDPhDFRCP, Guang Yang, PhD

Blood (2017) 130 (Supplement 1): 803.

https://doi.org/10.1182/blood.V130.Suppl_1.803.803

Published: 2017

Journal Articles

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

Todd Covey, PhD, Michael Gulranjani, Jean Cheung, Elena Bibikova, Tracy Clevenger, Fanny Krantz, Karen Pan, Kyoko Yamaguchi, Anouk De Jong, Bart Van Lith, Diana Mittag, Raquel Izumi, PhD, John C. Byrd, MD, William G Wierda, MD PhD, Susan M. O'Brien, MD, Richard R. Furman, MD, Allard Kaptein, PhD

Blood (2017) 130 (Supplement 1): 1741.

https://doi.org/10.1182/blood.V130.Suppl_1.1741.1741

Published: 2017

Journal Articles

CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients

Mariela Sivina, PhD, Ekaterina Kim, PhD, Claire Pacelli, Michael J. Keating, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3002.

https://doi.org/10.1182/blood.V130.Suppl_1.3002.3002

Published: 2017

Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E Witzig, MD, Lubomir Sokol, MD PhD, Eric Jacobsen, MD, Ranjana H. Advani, MD, Francine M Foss, MD, Rufino Mondejar, PhD, Miguel Angel Piris, PhDMD, James Bolognese, PhD, Francis Burrows, PhD, Linda Kessler, BA, Karen Bracken, MHS, Vishnu Mishra, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2017) 130 (Supplement 1): 2788.

https://doi.org/10.1182/blood.V130.Suppl_1.2788.2788

Published: 2017

NARROW

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd

The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

A Clinically-Indolent Variant of Extranodal NK/T Cell Lymphoma with Unique Immunophenotypic Profile and Superior Outcome

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)

Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients

TFL Deletion Induces Incredible CXCL13 Secretion and Cachexia in Vavp - Bcl2 T ransgenic Mice

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Defective Notch Activation in Mesenchymal Cells Contributes to Myeloproliferative Neoplasm in Aged Mice

BTK Cys481Ser Mutation Drives Ibrutinib Resistance through ERK1/2 Hyperactivation, and Can Confer a Protective Effect on Bystander Waldenstrom's Macroglobulinemia and ABC DLBCL Cells through Paracrine Mediated Pro-Survival Signaling

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only